Full Text (PDF)
Indian Journal of Preventive Medicine 13(1):p 7-8, Jan-June 2025. | DOI: 10.21088/ijpm.2321.5917.13125.1
Editorial
Prioritizing Prevention in Kidney Disease: A Physician’s Mandate
Author Information
Licence:
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
Indian Journal of Preventive Medicine 13(1):p 7-8, Jan-June 2025. | DOI: 10.21088/ijpm.2321.5917.13125.1
How Cite This Article:
Jyoti Prakash. Prioritizing Prevention in Kidney Disease: A Physician’s Mandate. J Prev Med. 2025; 13(1): 07-08.Timeline
Received : July 14, 2025
Accepted : August 10, 2025
Published : June 18, 2025
Abstract
Not available
References
- 1. Jager K.J., et al. A Single Number for Advocacy and Communication—Worldwide More than 850 Million Individuals Have Kidney Diseases. Kidney Int. 2019; 96(5): 1048–50. doi:10.1016/j. kint.2019.07.012.
- 2. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of CKD, 1990–2017. Lancet. 2020; 395(10225): 709–33. doi:10.1016/S0140-6736(20)30045-3.
- 3. Bikbov B., et al. Global, regional, and national burden of chronic kidney disease: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 395(10225): 709–733.
- 4. Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560–72.
- 5. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD. Kidney Int. 2022; 101(5S): S1–S127.
- 6. Sprint Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103–16.
- 7. Garofalo C, et al. Obesity and chronic kidney disease: From pathophysiology to management. J Nephrol. 2019; 32(2): 199–210.
- 8. Tangri N, et al. A Predictive Model for Progression of CKD to Kidney Failure. JAMA. 2011; 305(15): 1553–9.
- 9. Cass A., et al. The High Burden of CKD and End-Stage Kidney Disease in Indigenous Populations. Kidney Int. 2019; 96(5): 1041–7.
- 10. Heerspink H.J.L., et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383: 1436–46.
Data Sharing Statement
There are no additional data available.
Funding
This research received no funding.
Author Contributions
All authors contributed significantly to the work and approve its publication.
Ethics Declaration
This article does not involve any human or animal subjects, and therefore does not require ethics approval.
Acknowledgements
Information not provided.
Conflicts of Interest
The authors report no conflicts of interest in this work.
About this article
Cite this article
Jyoti Prakash. Prioritizing Prevention in Kidney Disease: A Physician’s Mandate. J Prev Med. 2025; 13(1): 07-08.
Licence:
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
| Received | Accepted | Published |
|---|---|---|
| July 14, 2025 | August 10, 2025 | June 18, 2025 |
DOI: 10.21088/ijpm.2321.5917.13125.1
Keywords
Search for Similar Articles
Similar Articles
- Recent Advances in Diabetes and Obesity Management
- Rhinosporidiosis in A 10-Year-Old Child: A Case Report Highlighting the Environm...
- Forensic Implications of Clinically Significant Diseases: From Sudden Cardiac De...
- Mindful Eating for Restorative Sleep: A Community-Based Approach to Sleep Hygien...
- Utilizing AI for Identifying and Addressing Health Disparities in Communities: A...
Article Level Metrics
Last UpdatedWednesday 17 June 2026, 21:46:17 (IST)
571
Accesses
6
144
00
Citations
NA
NA
NA
Download citation
Article Keywords
Keyword Highlighting
Highlight selected keywords in the article text.
Timeline
| Received | July 14, 2025 |
| Accepted | August 10, 2025 |
| Published | June 18, 2025 |
licence
Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
